Skip to main content

Table 1 Clinical characteristics of patients

From: Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus

Variables

 

Number of patients

13

Male, n (%)

5 (38%)

Age, years

62 ± 12

Body mass index, kg/m2

27 ± 5

Coronary risk factors

 Dyslipidemia, n (%)

7 (54%)

 Hypertension, n (%)

8 (62%)

 Current sumoker/past smoker

0/3 (23%)

Coronary artery disease

4 (31%)

 History of old myocardial infarction

0 (0%)

 History of PCI

3 (23%)

 History of CABG

1 (8%)

Anti-diabetic drugs

 DPP-4 inhibitors

5 (38%)

 α-Glucosidase inhibitors

1 (8%)

 Sulfonylureas

1 (8%)

 Biguanides

1 (8%)

 Glinides

1 (8%)

 Thizoladinediones

0 (0%)

 Insulin

2 (15%)

Statins

7 (54%)

Antihyperuricemics

3 (23%)

  1. PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, DPP-4 dipeptidyl peptidase-4
  2. Unless indicated otherwise, data are presented as mean ± standard deviation